Kuros Biosciences to present at upcoming clinical and investor conferences

 Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two […]

Weiterlesen

Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe

Agreements in Netherlands, Switzerland and Austria and letter of intent in Finland Supports further acceleration of sales of MagnetOs bone graft Kuros Biosciences (SIX: KURN) today announced that it has […]

Weiterlesen

Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week

. Industry-leading award recognizes Kuros’ Fibrin-PTH (KUR-113) technology Rounds off successful year of commercial, clinical, and financial progress Kuros also wins GHP Magazine’s 2020 International Life Science Award Kuros Biosciences […]

Weiterlesen

Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting

Kuros Biosciences today announced it will unveil new research on the role of osteoimmunology in bone formation in three presentations at the North American Spine Society (NASS) 2020 Annual Meeting, […]

Weiterlesen

Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing

Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, will host an expert perspectives webinar on pioneering solutions for targeted and controlled bone healing on Wednesday, October […]

Weiterlesen

Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft

Strong adoption by spinal surgeons since U.S. launch in September 2019 Sales accelerating with over 2,000 patients treated to date Kuros Biosciences (SIX: KURN) today announced that over 2,000 patients […]

Weiterlesen

Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH

First investigational trial of a drug-biologic bone graft for spine fusion Phase 2 trial in the U.S. compares Fibrin-PTH (KUR-113) with local autograft Primary endpoint is radiographic interbody fusion at […]

Weiterlesen